CD44 and neoplasm: The results show that among the 6 CSC markers investigated, the expression of CD44 and its variant isoforms (CD44v6 and CD44v8-10), and also ALDH1A1, were associated with tumor progression and poor outcome of CCA patients, including short RFS and OS.